UCI Health has launched a first-in-human, phase 1 clinical trial utilizing vascular targeted photodynamic therapy to treat localized, inoperable pancreatic tumors. Led by Dr. Nadine Abi-Jaoudeh at the Chao Family Comprehensive Cancer Center, the innovative procedure combines the light-sensitive drug padeliporfin with fiber-optic laser illumination to clear tumor-encased blood vessels and enable lifesaving surgery.
Roughly half of all patients present with localized disease that has not metastasized to distant organs. Yet, two-thirds of this population are deemed unresectable because their tumors encase critical abdominal arteries like the celiac axis or superior mesenteric artery. Attempting traditional surgical resection under these anatomical constraints carries an unacceptable risk of catastrophic hemorrhage, leaving patients with palliative care options that mirror the grim survival statistics of advanced metastatic disease.
Mechanisms of Action in Vascular Targeted Photodynamic Therapy
The experimental protocol relies on a precision-engineered two-step intervention designed to dismantle tumor vasculature from the inside out. Once distributed, an interventional radiologist threads a specialized balloon catheter directly into the tumor-encased artery. A fiber-optic laser positioned inside the balloon is activated for two five-minute increments. This illumination triggers a rapid photochemical reaction that generates reactive oxygen species, destroying the microvasculature feeding the tumor and causing selective necrosis of the malignant tissue.
Patient safety protocols require stringent post-treatment management. Following the dual five-minute laser activations, participants must remain in a strictly controlled dark room for three days. Unfiltered ambient light exposure during this clearance window can induce severe phototoxic skin reactions as the circulating drug clears systemic pathways. This photosensitivity profile currently limits the surface area and anatomical volume that can be treated safely in a single session.
In Plain English: The Clinical Takeaway
- Targeted Clearing: Doctors use a specialized laser inside a blood vessel balloon to activate a drug that shrinks tumors blocking vital surgical pathways.
- Surgical Bridge: The goal of this phase 1 trial is not an immediate cure, but shrinking the tumor enough to make surgical removal possible.
- Strict Recovery: Patients must stay in a dark room for three days post-treatment to avoid severe skin damage from lingering light-sensitivity.
Early Phase Results and Multidisciplinary Collaboration
Preliminary findings from the trial, documented in the Journal of Vascular and Interventional Radiology, initially detailed outcomes for three participants. The cohort has since expanded to six patients. Of those six individuals, four successfully underwent subsequent surgical resection to remove residual tissue. Pathological examination revealed that three of the resected patients achieved clear surgical margins with no detectable evidence of cancer cells remaining at the perimeter.
Dr. Nadine Abi-Jaoudeh serves as the principal investigator for the study at the UCI Health Chao Family Comprehensive Cancer Center, one of only two medical institutions in the United States evaluating this specific technology. The trial protocol tests three incremental doses of laser illumination to establish optimal biological effect and safety thresholds. The research team operates within a comprehensive multidisciplinary framework, featuring medical oncologist Dr. Jennifer B. Valerin alongside surgical specialists Dr. David K. Imagawa and Dr. Zeljka Jutric.
The investigative team coordinates closely with regulatory and institutional oversight bodies to evaluate whether dose-escalation data will support broader phase 2 and phase 3 evaluation frameworks regulated by the U.S. Food and Drug Administration (FDA).
| Metric | Trial Data |
|---|---|
| Trial Phase | First-in-Human, Phase 1 |
| Primary Drug | Padeliporfin |
| Laser Delivery | Two 5-minute increments via intravascular balloon |
| Total Cohort Size (Reported) | 6 Patients |
| Patients Proceeding to Surgery | 4 Patients |
| Negative Margins Achieved | 3 Patients |
Contraindications & When to Consult a Doctor
Vascular targeted photodynamic therapy is an investigational intervention strictly confined to clinical trial protocols.
Clinical trial expansion depends on sustained safety data and reproducible surgical downstaging across larger cohorts.
References
- Journal of Vascular and Interventional Radiology: Preliminary Findings on Vascular Targeted Photodynamic Therapy in Unresectable Pancreatic Malignancies.
- U.S.
Disclaimer: This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare provider regarding any clinical condition or participation in clinical trials.
